ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Changes in opioid prescribing and high-risk co-prescribing after implementation of the 2016 CDC opioid guideline among older adults with and without cancer.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo evaluate changes in opioid prescribing and high-risk opioid co-prescribing before and after the 2016 CDC Guideline among Medicare beneficiaries with and without cancer.
methodsUsing SEER-Medicare data (2014-2017), we identified beneficiaries diagnosed with breast, colon, or lung cancer and a comparison cohort without cancer. All patients were continuously enrolled in Medicare Parts A, B, and D and not enrolled in Medicare Advantage. The pre-policy period was January 2014-November 2015 and the post-policy period was April 2016-September 2017. Outcomes assessed within 3 months of diagnosis or index claim included monthly opioid prescribing rates, monthly days of opioid supply, daily morphine milligram equivalents (MME), and high-risk co-prescribing with benzodiazepines, antidepressants, or non-benzodiazepine sedatives. Difference-in-difference models compared changes between groups before and after guideline implementation, adjusting for baseline characteristics.
resultsThe study included 42,931 cancer and 108,218 patients without cancer. After guideline implementation, opioid prescribing declined in both groups but more substantially among patients without cancer, while changes among patients with cancer were minimal. Difference-in-difference estimates indicated smaller reductions among cancer versus patients without cancer in monthly opioid prescribing (- 0.14; 95% CI, - 0.17 to - 0.11; p < 0.0001) and days of supply (- 3.07; 95% CI, - 3.68 to - 2.45; p < 0.0001). Changes in daily MME did not differ significantly (16.73; 95% CI, - 43.36 to 76.82; p = 0.5853). High-risk co-prescribing declined overall but decreased less among patients with cancer for opioid-benzodiazepine, opioid-antidepressant, and opioid-non-benzodiazepine sedative combinations (all p < 0.0001).
conclusionFollowing the 2016 CDC guideline, reductions in opioid prescribing and high-risk co-prescribing were greater among patients without cancer, with minimal change observed among patients with cancer.
Indexed as
Identifiers
42850338What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.